Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 7kWORD 27k
18 December 2017
Answer given by Mr Moedas on behalf of the Commission
Question reference: E-006901/2017

The Commission is aware of the study on myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) referred to by the Honourable Member, which was published in the scientific journal PLOS One(1). As a matter of policy, the Commission does not assess the results of individual research projects that do not relate directly to its funding activities.

Neither is the Commission in a position to comment on budget allocations by third party research funding agencies, although it is in a regular contact with some of them, such as the US National Institutes of Health (NIH) or the Canadian Institutes of Health Research (CIHR).

To date, no specific projects on ME/CFS have been supported by the EU Framework Programmes for Research and Innovation. However, the project GLORIA(2) is investigating the pathophysiology of chronic pain conditions including fibromyalgia.

Horizon 2020, the framework Programme for Research and Innovation (2014-2020)(3), provides opportunities for supporting research on ME/CFS, fibromyalgia as well as other neuro-immunological disorders, including better diagnostics and care. The bottom-up approach of the Horizon 2020 calls for proposals provides applicants with freedom in the choice of their investigations. More information can be found at the Research and Innovation Participant Portal(4).


Legal notice